The North Central London Joint Formulary Committee – NCL JFC – advises Commissioners and Provider Trusts in NCL on appropriate, equitable, evidence-based and cost-effective medicines use. The JFC scientifically assesses medicines in terms of comparative efficacy, safety, convenience and cost-effectiveness. The current remit of JFC is thus scientific and advisory in nature and hence makes recommendations to accountable budget holders. The JFC is driven by an evidence-based approach and new medicines will be recommended if they offer a significant advantage over existing products. If the NHS is to afford to pay for new medicines which are expensive but offer a real clinical advantage we need to rigorously exclude those which incur cost but are essentially ‘me-too’ drugs and/or offer no clear advantage.
The triage process by which new drug applications are distributed between local Trust Drugs and Therapeutics Committee (DTCs) and NCL JFC is provided below.